Livzon Pharmaceutical Group ( (HK:1513) ) has shared an announcement.
Livzon Pharmaceutical Group Inc. has released its unaudited financial results for the first quarter of 2025, reporting a slight decrease in operating income by 1.92% compared to the same period last year. However, the company saw an increase in net profit attributable to shareholders by 4.75%, indicating improved profitability despite a decline in net cash flow from operating activities by 21.59%. The company’s total assets and owners’ equity also showed marginal growth, reflecting a stable financial position.
More about Livzon Pharmaceutical Group
Livzon Pharmaceutical Group Inc. is a joint stock company incorporated in the People’s Republic of China, operating in the pharmaceutical industry. The company, along with its subsidiaries, focuses on the development, production, and sale of pharmaceutical products, with a market presence on the Stock Exchange of Hong Kong Limited.
YTD Price Performance: -0.29%
Technical Sentiment Signal: Buy
Current Market Cap: $3.93B
For a thorough assessment of 1513 stock, go to TipRanks’ Stock Analysis page.